Araris Biotech AG, a company pioneering antibody-drug conjugate (ADC)-linker technology, today announced it has received an additional CHF 12.7 million in seed financing, bringing the total amount raised to CHF 15.2 million.
The investment round was led by Pureos Bioventures with participation from new investors 4BIO Capital, btov Partners and existing investors Redalpine, VI Partners and Schroder Adveq.
The proceeds will be used to nominate a clinical candidate and advance Araris’ lead program into preclinical and clinical development. The new funds will also support the development of a broad proprietary pipeline of ADC compounds.
Read more here.